Hologic: The Future of 3D Mammography and Molecular Diagnostics—What’s Next? 

Hologic, Inc. reported its first-quarter fiscal 2025 results, reflecting both positive operational efficiencies and some challenges impacting revenue streams. The overall revenue for the quarter came in at $1.022 billion, marking a modest 1% increase on a constant currency basis. Noteworthy is the impact of the stronger U.S. dollar, which reduced reported revenue by about $9 million. Despite the revenue figures being at the lower end of expectations, the company’s non-GAAP earnings per share stood at $1.03, positioned at the high end of guidance and reflecting a 5% increase. This growth in earnings per share was supported by a 90 basis points improvement in non-GAAP operating margins and bolstered by strategic share repurchases and favorable foreign exchange hedges.